Juno Therapeutics (JUNO) stock had a bullish inflow of $55.55 million worth of trades on uptick and an outflow of $52.27 million in downticks on Thursday. The total uptick to downtick ratio stood at 1.06. The net money flow into the stock was $3.28 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $1.36 million. An inflow of $1.16 million block trade was recorded on downticks. $2.52 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 2.17 in favor of the bulls. However, Juno Therapeutics (JUNO) stock traded down $1.71 , and reached $28.71, a drop of -5.62% over the previous day. On a weekly basis, the stock is 3.24%, over the previous weeks close.
The stock has recorded a 20-day Moving Average of 25.19% and the 50-Day Moving Average is 28.04%. Shares have dropped -48.17% from its 1 Year high price. On Dec 1, 2015, the shares registered one year high at $57.82 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $41.36 and the 200 Day Moving Average price is recorded at $38.34.
Juno Therapeutics (NASDAQ:JUNO): The stock opened at $30.84 on Thursday but the bulls could not build on the opening and the stock topped out at $30.97 for the day. The stock traded down to $28.30 during the day, due to lack of any buying support eventually closed down at $28.80 with a loss of -5.33% for the day. The stock had closed at $30.42 on the previous day. The total traded volume was 7,056,417 shares.
In an insider trading activity, Klausner Richard, director of Juno Therapeutics, Inc., unloaded 12,000 shares at an average price of $40.71 on June 24, 2016. The total amount of the transaction was worth $488,520, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.